Contract 75A50123C00037
Emergent Product Development Gaithersburg Inc. · Department Of Health And Human Services · June 24, 2024
Emergent Product Development Gaithersburg Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on June 24, 2024 for $41.91 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Gaithersburg, MD. It was awarded under full and open competition. The contract has been modified 3 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on February 5, 2026. If all options are exercised, the contract could reach $1.53 billion.
Contract details
- PIID
- 75A50123C00037
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- Place of performance
- Gaithersburg, MD
- First action
- June 24, 2024
- Latest action
- February 5, 2026
Description
THE PURPOSE OF THIS NO-COST MODIFICATION IS TO UPDATE SEVERAL ARTICLES.
Modification timeline
-
February 5, 2026Mod P00010 · Other Administrative Action$118.56M
-
July 8, 2025Mod P00009 · Other Administrative ActionTHE PURPOSE OF THIS NO-COST MODIFICATION IS TO ARTICLE G.11 NEGOTIATED INDIRECT COST RATE TO MATCH DOCUMENTATION FROM NIH DATED MARCH 19, 2025.$118.56M
-
August 30, 2024Mod P00005 · Exercise An OptionTHE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION 1/CLIN0002 AND UPDATE ARTICLE B.3 ESTIMATED COST PLUS FIXED FEE CLINS.$101.89M
-
June 24, 2024Mod P00004 · Other Administrative ActionTHE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLES B.5. ADVANCE UNDERSTANDINGS (H) QUALITY AGREEMENT SHALL BE SUBMITTED FOR APPROVAL NO LATER THAN OCTOBER 31, 2024, F.2. VMI PLAN TO BE SUBMITTED F…$59.97M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Amgen USA Inc | 1 | $59.99M |
| 2 | Vericel Corporation | 1 | $34.88M |
| 3 | Spectral Md, Inc. | 1 | $31.67M |
| 4 | Ppd Development Lp | 6 | $31.12M |
| 5 | L3 Technologies, Inc. | 1 | $22.00M |
| 6 | Technical Resources International, Inc. | 6 | $21.80M |
| 7 | Abbott Laboratories | 1 | $21.01M |
| 8 | Paratek Pharmaceuticals, Inc | 1 | $17.47M |
| 9 | Ossium Health, Inc. | 1 | $12.39M |
| 10 | Rho Federal Systems Division Inc | 1 | $8.00M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50123C00037?
Contract 75A50123C00037 is a federal contract awarded to Emergent Product Development Gaithersburg Inc. by Department Of Health And Human Services on June 24, 2024 for $41.91 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 3 times since the base award.
Who won contract 75A50123C00037?
Emergent Product Development Gaithersburg Inc. won contract 75A50123C00037 from Department Of Health And Human Services.
How much is contract 75A50123C00037 worth?
Contract 75A50123C00037 has obligated $41.91 million to date, with a total potential value of $1.53 billion if all options are exercised.